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Every year, 28 February is Rare Disease Day around the globe. In 
many high-income countries, significant programmes of research 
and policy have been developed to understand and meet the needs 
of individuals who live with rare diseases. In South Africa (SA), 
rare diseases have unfortunately not reached the awareness of most 
policy-makers and health system planners. On the one hand, it seems 
relatively easy to understand why rare diseases have remained ‘rare’ in 
SA, given the very high burden of other diseases, both communicable 
and non-communicable. On the other hand, we may be able to learn a 
lot by studying and treating rare disorders, sometimes with profound 
clinical consequences.
A careful look will identify many lessons we can learn from 
rare diseases.[1] Rare diseases are defined as conditions that have a 
prevalence less than 1/2 000. To date between 6 000 and 8 000 rare 
diseases have been identified, with characteristics that include a broad 
range of physical manifestations (e.g. renal, lung, cardiac and central 
nervous system involvement), neurodevelopmental manifestations (e.g. 
intellectual disability, autism, specific learning disorders) and mental 
health disorders (e.g. depression, psychosis and anxiety disorders). The 
first lesson, therefore, is that while these diseases are individually rare, 
they are collectively quite common, occurring in perhaps as many as 1 
in 20 individuals at some point in their life. The second lesson is that 
many rare diseases share common pathophysiological mechanisms. A 
new discovery in one rare disorder may therefore also have a direct 
impact on another. The tuberous sclerosis complex (TSC) story is a 
case in point here. The third lesson is that the study of rare diseases 
can lead to improved understanding of common diseases.[1] A perfect 
example here is the relationship between trisomy 21 (Down syndrome) 
and high rates of Alzheimer’s disease, which led to the discovery of the 
molecular basis of familial Alzheimer’s.[2]
An important feature of the majority of rare diseases is that they 
are chronic conditions, typically lifelong. Not only that, but many rare 
genetic disorders are also associated with multi-system involvement, 
sometimes referred to as ‘chronic multi-morbidity’. [3] There is global 
acknowledgement of the needs of individuals with chronic condi-
tions, and a strong imperative from the World Health Organization 
for all countries to meet these chronic needs.[4] However, it is clear 
that, even with good policies, there is a mismatch between policy and 
implementation in the majority of low- and middle-income countries, 
including SA.[3,5,6]
So, what about TSC? TSC is a rare genetic disorder, associated 
with very obvious ‘chronic multi-morbidity’ (see de Vries et al.[7] 
in this issue of SAMJ). The majority of individuals with TSC are 
diagnosed in the first few years of life, but some are not diagnosed 
until adolescence or adulthood. Most people with TSC will have 
involvement of the brain, skin and kidneys, and almost all will have 
some TSC-associated neuropsychiatric disorders (TAND), including a 
wide range of behavioural, psychiatric, neurodevelopmental, scholastic 
and psychosocial difficulties.[8] With a birth incidence of 1  in 6 000 
TSC is relatively common for a rare disorder, but  the majority of 
healthcare professionals will nevertheless see no or perhaps one case 
in their professional career. The disorder remained relatively obscure 
until the early 2000s, when the molecular mechanisms of TSC were 
identified, showing that the two proteins directly affected, TSC1 and 
TSC2, are key regulators in a funda mental intracellular signalling 
pathway, the mTOR (mammalian target of rapamycin) pathway.[7] This 
pathophysiological discovery led remarkably rapidly to the identification 
of molecularly targeted treatments for TSC – medications that speci-
fically and directly inhibit mTOR to reduce the overactivation resulting 
from deficits in TSC1 or TSC2 proteins. The mTOR proteins have 
since also been shown to be involved in neurofibromatosis type 1 and 
fragile X syndrome (two other rare genetic disorders), in response to 
cannabis (a rather common pheno menon), and in longevity.[9-12]
The clinical challenges for individuals with TSC, however, remain. 
Given that most healthcare professionals will never have diagnosed 
or treated someone with TSC, people are undiagnosed, misdiagnosed 
or diagnosed very late. Treatment is often inadequate or wrong. 
For example, a recent case report[13] in the SAMJ was clearly a case 
of an adolescent with TSC, facial angiofibromas and a presumed 
fat-poor angiomyolipoma (a non-cancerous tumour that should be 
treated with an mTOR inhibitor). However, this would have been 
obvious only to professionals who have seen and treated numerous 
individuals with TSC.
An interdisciplinary group of clinicians and TSC researchers 
have recognised the significant challenges of living with TSC in 
SA (and other low-resource countries). We acknowledge that these 
rare genetic disorders are not health priorities in SA, even though a 
systematic approach to the chronic multi-morbidity of rare diseases 
would probably lead to significant cost savings and improvements 
in quality of life for people with TSC. However, conscious that 
there were well-regarded international consensus guidelines for the 
diagnosis, monitoring and treatment of TSC,[14,15] we set out to draft 
a clinical update summarising an evidence-based and international 
consensus approach to the assessment and treatment of TSC.[7]
We realised that the majority of people with TSC in SA are probably 
cared for by general practitioners, and only a few by specialists. For 
that reason, we were keen to generate a broad and general document 
that we hoped would assist general practitioners, specialists, families 
and individuals with TSC. As one of our anonymous reviewers said, 
‘The document is about creating awareness and clinical support to 
fellow clinicians.’
15 May every year is Tuberous Sclerosis Complex Global Aware-
ness Day. We sincerely hope that this editorial and the CME article 
published in this issue of SAMJ will 
help to raise awareness of TSC, while 
at the same time remin ding us of 
the needs of all South Africans who 
live with chronic, multi-morbid rare 
genetic disorders.
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